NervGen Pharma NGEN 深 沪
等待开盘 10-12 09:30:00 美东时间
1.73
-0.020
-1.14%
华盛通- 最 高1.80
- 今 开1.75
- 成交量 29.32万股
- 最 低 1.705
- 昨 收 1.75
- 总市值 1.86亿
- 52周最高 6.30
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 1.58
- 委 比 72.31%
- 总股本 1.08亿
- 历史最高 6.30
- 量 比 0.88
- 振 幅 5.43%
- 历史最低 1.58
- 每 手 1
- 风险率 1.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NervGen Doses First Participant In Phase 3 RESTORE Study Of NVG-291 For Chronic Cervical SCI; Enrollment Completion Expected In H2 2027, Topline Data In H1 2028
RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injury Study builds on functional improvements observed in the placebo-controlled Phase 1b/2a CONNECT SCI study, with FDA alignment on the P...
30分钟前
NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026
Adjustments have no impact on cash and cash equivalents, cash runway, or business operations. Restatement is expected to reduce previously reported stock-based compensation expense, warrant liabilities, and accumulated deficit. VANCOUVER, British Columbia, Sept. 25, 2026 (GLOBE NEWSWIRE) -- NervGen ...
09-26 04:34
美股大行评级 | 美银上调AMD目标价从550美元升至620美元；IBM暴跌25%！大摩上调目标价升至293美元，汇丰下调评级至"卖出"目标价降至191美元
今日重点评级关注：Keybanc：维持迈威尔科技"超配"评级，目标价从385美元升至400美元；丰业银行：维持科尔黛伦矿业"跑赢大市"评级，目标价从27.5美元升至28.5美元
07-15 10:22
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
Leerink Partners Initiates Coverage On NervGen Pharma with Outperform Rating, Announces Price Target of $10
Leerink Partners analyst Marc Goodman initiates coverage on NervGen Pharma (NASDAQ:NGEN) with a Outperform rating and announces Price Target of $10.
07-14 01:59
NervGen Pharma Increases Mixed Shelf Offering From $150M To $250M
U.S.$250,000,000Common SharesDebt SecuritiesSubscription ReceiptsWarrantsUnitsThe amended and restated short form base shelf prospectus dated December 15, 2025 (the "Prospectus") of NervGen Pharma Corp. ("NervGen"
05-26 21:31
Why Is NervGen Pharma Stock Gaining Tuesday?
NGEN stock climbs as NervGen Pharma NVG-291 hits a 100% responder rate in spinal cord injury gait analysis. Phase 3 set for mid-2026.
05-26 20:33
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Akari Therapeutics (NASDAQ:AKTX) stock increased by 40.3% to $7.21 dur...
05-22 05:06
NervGen Pharma Announces Commencement Of Public Offering Of Common Shares
The offering is being made pursuant to a prospectus supplement to an amended and restated short form base shelf prospectus dated December 15, 2025 (the "Base Shelf Prospectus") filed in all of the provinces and
05-22 04:06
